LABEL for Ketamine, roll

STD SDDCLABLKETA1

Valid Article

Single use
A single-use device, also referred to as a disposable device, is intended for use on one patient during a single procedure. It is not intended to be reprocessed (i.e., cleaned and disinfected or sterilized).
12
Shelf life = length of time a product can remain active and effective. Short shelf life = shelf life = < 24 months
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
The product is part of at least one Kit. A kit is a collection of products (medical and/or logistic) that are needed for a certain intervention in emergency. The choice and quantity of the articles reflects the MSF protocols for this specific situation. The use of Kits allows to start an intervention without a detailed evaluation.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

LABEL for injectable drugs

Definition

Pre-printed label (according to ISO standards) for correct identification of injectable medicines in the perioperative area, in order to reduce medication errors.

Specifications

Quality Standards Comment

ASTM D4267 - 07(2015): Standard Specification for Labels for Small-Volume (100 mL or Less) Parenteral Drug Containers.

ISO 26825:2020: Anaesthetic and respiratory equipment -- User-applied labels for syringes containing drugs used during anaesthesia -- Colours, design and performance.

Technical specifications

  • The label must be self-adhesive.
  • If the labels are supplied in tape form, the place where the tape is to be cut between the labels must be perforated or clearly marked.
  • If there is backing material, the label must be easily detachable from it and from adjacent labels.
  • The label material should allow the user to write additional information (e.g. drug concentration) on the label with a ball-point pen, without smudging or blurring.
  • Background colours and patterns should be in accordance with ISO specifications. The background colour must not be such as to impair the legibility of any additional information on the label using a black ball-point pen.
  • To designate a drug of opposite action (including antagonists), use 1 mm wide diagonal stripes of the designated colour, alternating with 1 mm wide white stripes. At least the top 20 % of the label should be marked with diagonal stripes. The top of the drug name must be separated from the diagonal stripes by at least 0.5 mm.
  • Each label should be between 25 mm and 40 mm in length and between 10 mm and 15 mm in width.
  • The height of the letters of the drug name should be as large as possible and not less than 2.5 mm in a plain font (sans serif) with similar proportions of line and space within the letters (bold or semi-bold style):
    • lower case letters with an initial upper case letter
    • lower case letters with the distinctive parts of similar drug names in upper case letters (so-called 'tall-man' lettering)
    • all-upper case lettering should not be used
  • Except for drugs of opposite action (including antagonists), the drug name should be printed in the upper half of the label to allow space for writing the strength of the drug.
  • All letters should be black except for the labels for suxamethonium and adrenaline, which should be printed on the background colour with inverted bold letters in a black bar running from one edge of the upper half of the label to the other, with the rest of the label showing the coloured background.
  • The concentration unit can be pre-printed at the bottom right corner of the label​.

Note for Tall Man Lettering:

There is a lack of standardisation regarding the name pairs to be included and the letters to be in uppercase. It is recommended to follow the list provided by the FDA and IMSP (Institute for Safe Medication Practice): DOPamine, diazePAM, ePHEDrine and fentaNYL.

Others are proposed by the CCWG: KETAmine, PROPofol, THIOpental, MIDAzolam, ATRAcurium, VECUronium, SUXAmenthonium (= succinylcholine), NEOstigmine, MORPhine, NALoxone, LIDOcaine, BUPIvacaine, ONDAnsetron, DEXAmethasone, aTROPine, PHENylephrine, ADREnaline, ANTIbiotic, OXYTocin.

Packaging & Labelling

Presentation in rolls. The number of labels per roll varies according to the manufacturer: 400 to 1000 labels per roll.

The quantity to be ordered should be the number of rolls (not the number of labels).

Some rolls are presented in dispenser boxes, while other manufacturers offer different models of label dispensers for 6 to 24 rolls.

To be Ordered Separately

Dispensor for syringe labels

Instructions for use

Some restricted information has been hidden. Sign in to see this information

Storage

  • Below 25°C - Protect from sunlight - Protect from humidity
  • Keep the labels in their protective packaging, away from dust, until their use.

MSF requirements

The purpose of these recommendations is to standardise the labelling and facilitate the identification and differentiation of syringes and containers (bags, bottles, etc.) containing injectable medicines used in anaesthesia in order to reduce the risk of medication errors within MSF projects.

These recommendations are applicable in the operating theatres, recovery rooms, anaesthesia and sedation outside the operating rooms in MSF projects.

Some restricted information has been hidden. Sign in to see this information